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By passaging microcell hybrids (MCHs) containing human chromo-
some 3 (chr3) on A9 mouse fibrosarcoma background through
severe combined immunodeficient (SCID) mice (elimination test),
we have previously defined a 1-Mb-long common eliminated
region 1 (CER1) at 3p21.3, a second eliminated region (ER2) at
3p21.1-p14 and a common retained region (CRR) at 3q26-qter. In
the present work, chr3 was transferred by microcell fusion into the
human nonpapillary renal cell carcinoma line KH39 that contained
uniparentally disomic chr3. Four MCHs were generated. Compared
with KH39, they developed fewer and smaller tumors, which grew
after longer latency periods in SCID mice. The tumors were ana-
lyzed in comparison with corresponding MCHs by chr3 arm-specific
painting, 19 fluorescent in situ hybridization (FISH) probes, and 27
polymorphic markers. Three MCHs that maintained the intact
exogenous chr3 in vitro lost one 3p copy in all 11 tumors. Seven of
11 tumors lost the exogenous 3p, whereas four tumors contained
mixed cell populations that lacked either the exogenous or one
endogenous KH39 derived 3p. In one MCH the exogenous chr3
showed deletions within CER1 and ER2 already in vitro. It remained
essentially unchanged in 8y9 derived tumors. The third, exogenous
copy of the 3q26–q27 region (part of CRR) was retained in 16y20
tumors. It can be concluded that the humanyhuman MCH-based
elimination test identifies similar eliminated and retained regions
on chr3 as the humanymurine MCH-based test.
In collaboration with Henry Harris, we have shown thatfusion of normal cells with malignant cells has led to regular
suppression of tumorigenicity as long as the hybrid chromo-
some complement was maintained (1). Suppression of tumor-
igenicity was not associated with impairment of in vitro growth.
Following the loss of normal parent-derived chromosomes,
tumorigenicity reappeared. Stanbridge and colleagues (2)
showed subsequently that tumorigenicity can also be sup-
pressed by the introduction of single normal cell-derived
chromosomes via microcell fusion. Reappearance of the tu-
morigenic phenotype was associated with the loss of the
transferred chromosome or its parts.
To analyze the role of one of the most frequently deleted
regions in human tumors, which is located on the short arm of
human chromosome 3 (chr3), we have generated microcell
hybrids (MCHs) with the malignant mouse fibrosarcoma cell A9
as the recipient. Measuring the suppression of tumorigenicity
caused by the introduced chromosome is difficult however,
because the exogenous chromosome or parts of it keep being
eliminated. We have therefore chosen to identify regularly
eliminated regions instead. In contrast to the intact chr3 carried
by most MCHs in vitro, severe combined immunodeficient
(SCID)-derived tumors contained only human chromosome
fragments translocated to various mouse chromosomes. Marker
analysis showed that a '43-cM segment was missing from all
tumors. Studying additional tumor panels, the common elimi-
nated region was narrowed down to about 1 Mb [designated
common eliminated region 1 (CER1)] and covered by a single
PAC contig (3–6). A second eliminated region, missing from
most but not all tumors, has been found at 3p21.1-p14 and
designated second eliminated region (ER2) (4). In addition to
the eliminated regions, we could also identify a common re-
tained region (CRR) of '40 cM, at 3q26-qter. It was regularly
retained in 85y92 tumors and was present even after 4 consec-
utive SCID–SCID passages (7).
So far all elimination tests were performed on mouse A9
fibrosarcoma-based MCHs carrying a single human fibroblast-
derived chr3. In the present study we have set out to check the
validity of the elimination test on human chr3yhuman tumor
MCHs. We have chosen the nonpapillary or clear cell type of
renal cell carcinoma (RCC), where 3p losses occur in most
tumors (8, 9). We have transferred a normal human chr3 from
a monochromosomal chr3ymouse A9 fibrosarcoma hybrid
(A9-Hytk3) into the human nonpapillary RCC line KH39. We
have established four in vitro propagated MCHs (designated
YYKs) and analyzed the chr3 changes after tumor growth in
SCID mice.
Materials and Methods
Cell Lines and Microcell-Mediated Chromosome Transfer. A9Hytk3 is
a microcell hybrid that contains a single cytogenetically intact
human chr3 on mouse fibrosarcoma A9 background (10). It was
used as a chr3 donor by microcell fusion as described (2). The
conventional (nonpapillary or clear cell) renal cell carcinoma
line KH39 served as the recipient. Microcell hybrid lines were
selected on 400 mgyml Hygromycin B (Sigma). Four MCHs,
designated as YYK1, -2, -3, and -4, were obtained from four
different fusion events.
Tumorigenicity Tests. Six-week-old SCID mice were used for the
inoculations (106 cells per site). Both single-site and four-site
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inoculations were performed. In the latter case, each mouse
received three MCH samples and one parental RCC (KH39)
control. SCIDs were observed for tumor formation once a week
up to 20 weeks. The tumors were excised under sterile condi-
tions, explanted, and expanded for chromosome and DNA
preparations.
Polymorphic Marker Analysis. Microsatellite markers were either
end-labeled by [g-32P]dATP using T4 polynucleotide kinase
(Amersham Pharmacia) or by fluorescent (6-FAM, HEX, and
TET) dyes. One [g-32P]dATP end-labeled primer (0.2 pmol) was
used for PCR in a 20 ml volume containing 50–100 ng template
DNA, 2 pmol of each primer, 0.2 mM dNTP, and 1.7 units Taq
DNA polymerase (Amersham Pharmacia). The PCR program
was as follows: 95°C for 5 min, 30 cycles of 3 steps (95°C for 30
sec, 55°C for 1 min, and 72°C for 1 min), and 72°C for 7 min for
the last extension. PCR reaction (1–2 ml) was separated with 6%
denatured polyacrylamide gel and the gel was exposed to the
x-ray film. Signals were visualized after 24 h. Fluorescent dye-
labeled primer (2 pmol) was used in a 10-ml volume containing
5–10 ng template DNA, 0.2 mM dNTP, and 0.5 unit of AmpliTaq
Gold (Perkin–Elmer). The PCR program was: 95°C for 10 min,
30 cycles with 95°C for 30 sec, 55°C for 30 sec, and 72°C for 30
sec; final elongation 72°C for 7 min. PCR products (1–2 ml) from
each reaction were grouped according to the sizes of products
and separated with 5% denatured polyacrylamide gel on ABI
377 (Perkin–Elmer) using GENE SCAN software. Allele sizes were
determined by GENOTYPER 2.1 (Applied Biosystems). Some
primers were elongated by using terminal-transferase and co-
valently labeled with peroxidase and used to probe membranes
after transfer from the gel (ECL kit; Amersham Pharma-
cia) (11).
Allele Band Densitometry. A Molecular Dynamics Personal Den-
sitometer SI (Amersham Pharmacia) was used to measure the
density of allele bands.
Long Genomic Fragment Amplification. To prepare fluorescent in
situ hybridization (FISH) probes for the analysis of the lacto-
transferrin (LTF) gene, the Expand Long Template PCR System
kit (Roche Molecular Biochemicals) was used. The LTF exon
6–12 primers were: forward, 59-CTGGAGACGTGGCTTT-
TATCAG-39; reverse, 59-CTTGCCTTTCACAGATTCAG-39.
PCR conditions were designed as suggested by the manufacturer.
DNA from PAC RP6–19p19 was used as a template. The size of
product was '9 kb (designated LTF 6–12).
FISH. Probes were labeled by nick-translation with either biotin-
dUTP (Bionick labeling system, BRL) or digoxigenin-dUTP
(DIG-Nick Translation Mix, Roche Molecular Biochemicals).
Chr3 arm-specific painting was performed by using MCH B78-
MC56, which contains a t(3p;17q) on murine B78 melanoma
background (kind gift of Mario Chevrette, McGill University,
Montreal). B78-MC56-derived DNA was labeled with biotin and
detected by Cy3 conjugated avidin (red); MCH A9Hytk3 (carries
intact chr3)-derived DNA was labeled with digoxigenin and
detected by FITC-conjugated anti-digoxigenin antibodies
(green). Simultaneous FISH with these two probes painted 3p in
yellow, 3q in green, and 17q in red. Commercial chr3 painting
and centromere-specific probes labeled with fluorescein or Cy3
(Cambio, Cambridge, U.K.) were also used. One- and two-color
FISH was performed on metaphases and interphase nuclei
prepared from methanolyacetic acid fixed cell suspensions as
described (12). At least 20 metaphases and 50 nuclei were
analyzed for each sample.
Comparative genomic hybridization (CGH) was performed as
described (13).
Databases and Software. PCR markers were selected mainly from
the following databases: the genome database (GDB, www.
gdb.org); an STS-Based Map of the Human Genome (14) from
the Whitehead Institute (www.genome.wi.mit.eduycgi-biny
contigyphys-map). BLAST programs were used for database
searches on the National Center for Biotechnology Information
(NCBI)yNational Institutes of Health (NIH) server
(www.ncbi.nlm.nih.govycgi-binyBLAST). The PRIMERS soft-
ware (www.williamstone.comyprimersy) was used for primer
selection.
Results
Characterization of the Recipient KH39, Donor A9Hytk3, and the
chr3yKH39 MCHs: YYK1, -2, -3, and -4. In KH39, analysis of 35
polymorphic markers on 3p, 20 of which were published earlier
(13), and nine 3q markers has shown that the whole chr3 was
hemizygotic. In A9Hytk3 we have checked the intactness of the
human chr3 by 54 PCR markers (ref. 10 and unpublished data).
Cytogenetic methods, including G-banding, FISH painting, chr3
centromere probe, and 3p locus-specific probes on metaphases
and interphase nuclei, were used to monitor the presence and
intactness of transferred chr3. Two intact copies of chr3 were
found in KH39, one in A9Hytk3, and three in YYK2, -3 and -4
(Fig. 1a). In YYK1, the third copy of chr3 was rearranged. The
position of the centromere, banding pattern, and arm-specific
painting revealed a pericentric inversion accompanied by a
deletion(s) (Fig. 1c). CGH analysis of YYK1 vs. KH39 showed
a uniform 3p gain, although FISH with 19 locus-specific probes
detected two 3p deletions (Fig. 2). One of them overlapped
partially with CER1, whereas the second mainly corresponded to
ER2. G-banding, 3q painting, and CGH analysis suggested also
large 3q11–q21 and 3q27-qter deletions.
Tumorigenicity Tests. SCID-grown KH39 tumors had an average
take incidence of 86% after inoculation of 106 cells. As shown in
Table 1, YYKs had a mean take incidence of 39% (61 tumors per
155 inoculations). The latency time of the YYK tumors was 3–5
weeks, in contrast to KH39, which was regularly palpable after
1 week. The mean size of all tumors was significantly smaller
(only 4y20 exceeded 1 cm3) compared with KH39 tumors, which
reached 0.5–2.4 cm3 at the time of explantation. Only 20 of 61
YYK tumors were explanted successfully, in contrast to the
regularly explantable KH39.
Polymorphic Marker Analyses of Tumors. Fifty chr3-specific poly-
morphic microsatellite and restriction fragment length polymor-
phism (RFLP) markers were tested for their ability to differen-
tiate between the exogenous A9Hytk3-derived chr3 and the
endogenous chrs3 of the KH39. Altogether, 18 3p markers
(including three CER1 and two ER2 markers) and nine 3q
markers were informative. Twenty YYK-derived tumors were
analyzed (Figs. 3 and 4a). The tumors could be divided in three
groups (g, I–III)—g, I: tumors identical with the in vitro MCH
[YYK1 tu2–tu9; these had two deletions on 3p that affected the
exogenous chr3-derived alleles of D3S2354 (CER1), D3S1573,
and D3S1076 (ER2)]; g, II: tumors that lost most (YYK1 tu1 and
YYK2 tu1 and tu2) or all exogenous 3p alleles (YYK2 tu3,
YYK3 tu3, and YYK4 tu3–tu5); g, III: tumors that retained all
exogenous alleles (YYK2 tu4 and tu5 and YYK3 tu1 and tu2).
Three CRR (7) markers, D3S1763, D3S3053, and 3S1262,
remained heterozygous in all YYKs and in 16y20 tumors. Three
YYK4 derived tumors that lost the whole exogenous chr3 and
one YYK1 tu1 that lost all but four chr3 markers were the
exceptions.
FISH Analyses of Tumors. We have chosen representative tumors of
each group—g, I: YYK1 tu2, tu3, and tu4; g, II: YYK2 tu1, tu2,
and tu3 and YYK4 tu3 and tu4; and all tumors from g, III. The




























Fig. 1. FISH analysis of chr3 in A9Hytk3, KH39, YYKs, and 12 YYK-derived SCID tumors (groups I–III). Subpopulations (S1–20) were identified according
to the number and morphology of chrs3 (rearranged chromosomes are marked by arrows and magnified as black and white DAPI-banded images at the
corner of boxes). (a) Chr3 painting (green) and interphase FISH (red, RP6 –19p19; green, Rp6 –102f2) analyses of chr3 copy number in cell lines: A, A9Hytk3
(donor of chr3); K, KH39 (recipient); and YYK2 (one of the generated MCHs). (b) Arm-specific painting as described in Materials and Methods for the same
metaphase of YYK2. (c) Pericentric inversion in YYK1. (d) Loss of 3p in tumor cells (S8, S11). (e) Loss of CER1 on rearranged chr3 in tumors (S14, S15, S9)
shown by FISH with chr3 centromere (red) and CER1 PAC 188 g11 (green) probes on metaphases. ( f) Loss of the third copy of CER1 detected by interphase
FISH in YYK2 tu1 (same probes as in e). (g) Percentage of different cell subpopulations (S1–S20) in YYKs and derived tumors. Black patterns on bars:
minimum three intact chrs3. Color patterns: maximum two intact chrs3. Blue patterns: exogenous 3p rearranged in vitro (blue arrow in c). Red patterns:
exogenous 3p lost in vivo (red arrows in d and e). Green patterns: endogenous 3p loss (green arrows in d and e). White: other minor (,10%) subpopulations.
(h) Retentions vs. losses on 3q and 3p (black vs. gray, counted from g, II and g, III, results shown in g). Ratio of exogenous vs. endogenous 3p losses (red
vs. green, counted from total exogenous 3p losses in g, II and red vs. green bars in g, III shown in g). (i) Percentage of cells with minimum three signals
of: chr3 centromere (green) and CER1 PAC 188 g11(red) (based on interphase FISH as illustrated in c); intact chrs3 (blue) (based on metaphase FISH, shown
in a and b) in YYK in vitro lines, derived tumors, and original KH39 line.























tumors analyzed by morphology and copy number of chr3 were
found to contain 20 subpopulations (S1–S20 in Fig. 1 d, e, and
g). Chr3 arm-specific painting (Fig. 1b) detected two (sometimes
one) copies of intact chr3 (3p arm) in the majority of the cells
(Fig. 1 d, g, and blue bars in i) in all three groups and their
subpopulations. The third 3p was always lost (g, II and g, III) or
rearranged (g, I). For CER1 analysis, we used a combination of
centromere probe and PAC RP6–188 g11, located in the middle
of CER1. We detected chr3 centromere, but no PAC signal on
the rearranged chrs3 (Fig. 1e). By interphase FISH (Fig. 1f ), all
tumors had only two RP6–188 g11 signals (Fig. 1i, red bar),
whereas the centromeres were maintained in three copies (Fig.
1i, green bars), except YYK4 tu3 and tu4, which have eliminated
an entire chr3.
In agreement with polymorphic marker analysis in g, I, we
Fig. 2. FISH mapping of 3p deletions in YYK1. Probes are shown by numbers,
the corresponding names and locations are listed in fig 3. (a) Metaphase and
interphase FISH. Probe number and color as indicated. Signals on the rear-
ranged chr3 are marked by red arrows, on the normal chromosomes by green
arrows. (b) From left to right: CGH of YYK1 vs. KH39—gain over 3p and
3q21–27 (vertical green bars) and no gain (large deletions in additional chr3)
in the regions marked by vertical red bars. Green circles indicate retained FISH
probes on the rearranged chrs3, red lines show the positions of deleted CER1
and its borders (12 probes) and ER2 (deleted probe 30). Horizontal bars: % of
nuclei with 1–5 signals for different FISH probes. Final map of the CER1
deletion in kb scale (see ref. 6). Red lines indicate deleted probes; green lines
indicate retained probes; and red arrow indicates disrupted probes (probes 22,
23, and 24).
Fig. 3. Polymorphic (normal letters) and FISH (bold) marker analysis of
YYKs and 20 derived tumors divided in 3 groups (gI– gIII). Italics, relevant
genes. Microsatellite marker labeling: * by 32P, ¤ by fluorescence, # by
peroxidase (ECL kit). $, restriction fragment length polymorphism (RFLP)
marker; C, cosmid; P, PAC; N, NotI clone (references). Black boxes: two
alleles or minimum three FISH signals per cell. Light gray boxes: LOH or
maximum two FISH signals per cell. Dark gray boxes: two alleles, but loss of
one 3p copy by FISH. White boxes: not done (in YYK2 tumors, YYK3 tu1 and
tu2 and YYK4 tu4 and tu5 most of FISH markers were not tested, because
painting has shown an entire 3p copy loss).




























found no further significant changes compared with the in vitro
subpopulations (blue bars in Fig. 1g).
In a contrast to the LOH data, g, II and III did not differ by
FISH analyses. In both groups, loss of additional 3p copies
occurred in virtually 100% of cells, but 70% of cells still retained
3q (Fig. 1h). The heterozygosity was maintained in g, III,
indicating that an endogenous 3p was eliminated.
Analysis of Exo-yEndogenous 3p Losses. The tumors of g, III were
most heterogeneous, suggesting complex exo-yendogenous 3p
losses. Fig. 4b shows the densitometric analysis of four polymor-
phic markers in these tumors. The average ratio of two alleles
indicates no significant difference between the in vitro lines and
YYK2 tu4 and tu5, suggesting that the 3p loss found on
cytogenetic examination affected both endogenous and exoge-
nous chromosomes. In these tumors the S9 and S10 were
different from the S8, which was dominant in the YYK2-derived
tumors of group II. Therefore we consider that the S8 has lost
the exogenous 3p, whereas S9 and S10 have lost the endogenous
3p. In YYK3 tu1 the endogenous allele decreased from 77.1%
to 55.2%, suggesting a significant endogenous 3p loss on SCID
passage, which could occur in S11. In YYK3 tu2 the exogenous
allele density was reduced, suggesting that a minority of cells lost
endogenous 3p. S12, which had only two chr3 copies, was also
present in the YYK3 line. Because this was hygromycin-
resistant, the lost copy should be an endogenous chr3. The
‘‘zebra pattern’’ of exogenous allele losses in YYK2 tu1 and tu2
(Fig. 3) may be related to the pericentric inversion and interstitial
deletions on the rearranged chr3 (S7) in 10% or less of cells.
We may conclude that in g, III, loss of endogenous 3p has
occurred in 20–70% of cells (green bars in Fig. 1g). The rest of
the cells eliminated exogenous 3p (red bars in Fig. 1g). In all, the
11 tumors of g, II and g, III lost exogenous 3p in '80% of cells
and an endogenous 3p in '20% of cells (Fig. 1h).
Fine Mapping of CER1 Deletion in YYK1 and Derived Tumors. Meta-
phase and interphase FISH (Fig. 2), as well as polymorphic
marker analyses (Fig. 3), detected deletions inside CER1 and
ER2 in YYK1 and derived tumors. Five PACs from CER1 and
NL2–008 from ER2 were deleted on the rearranged chr3.
RP6–32 g23 (probe 19 in Fig. 2) gave an unusually small
hybridization signal. Both PAC 94k13 (probe 24) and RP6–
19p19 (probe 22), which contained a full length LTF gene, were
disrupted by the pericentric inversion. We have used two addi-
tional FISH probes, RP6–91p17 (probe 25), containing exons
1–6 of LTF, and a large size LTF fragment generated by PCR
(see Materials and Methods), including exons 6–12 (probe 23), for
further analysis of the gene. The latter detected a breakpoint
within the exon 6–12 region. As summarized in Fig. 2b, the
deletion is spanning over '700 kbp of CER1.
Discussion
CER1 and ER2 on 3p and CRR on 3q have been identified by
passaging the murine A9 fibrosarcoma cells that carried a single,
normal fibroblast-derived human chr3 in SCID mice (4, 5, 7).
Now, we tested whether the same regions were affected when a
human chr3 hemizygous tumor cell (the RCC line KH39) was
used as the recipient of a normal chr3. By tumorigenicity tests we
found that the introduction of a normal chr3 reduced the take
incidence of KH39 and prolonged the latency period, in line with
earlier findings (reviewed in refs. 15 and 16). In contrast to
earlier data (17), however, in vitro growth was not inhibited.
These findings were consistent with our earlier findings with
somatic cell hybrids derived from the fusion of normal and
malignant cells that grew in vitro as well as the parental tumors,
but were low or nontumorigenic in vivo.
The analysis of the successfully explanted tumors has shown that:
(i) All 11 tumors derived from MCHs YYK2, -3, and -4 that carried
an intact exogenous chr3 before inoculation eliminated one 3p copy
after SCID passage; (ii) all nine tumors derived from YYK1, which
carried an exogenous chr3 with CER1 and ER2 deletions in vitro,
grew in SCID mice without further chromosome changes; and (iii)
exogenous 3q26-q27 was retained in 16y20 tumors.
These findings indicate that 3p regions present in YYK2, -3,
and -4, but absent in YYK1 (hhCER1 and hhER2) may com-
plement 3p-associated genetic defect(s) that is mandatory for the
tumorigenicity of KH39.
The telomeric border of CER1 was the same in the humany
human and humanymurine systems. The centromeric border of
hhCER1 is '250 kb more distal. It contains the genes KIAA0028,
leucyl-tRNA synthetase and LIMD1, LIM domain containing 1
(18), CCR1, CCR3, CC-chemokine receptors (6), KIAA0851ySAC1,
suppressor of actin in yeast LZTFL1, leucine zipper transcription
factor-like 1, XT3, orphan transporter and CCR9, and CC-
chemokine receptor 9 (H.K. et al., unpublished observations). LTF
(lactotransferrin) or LF (lactoferrin) was disrupted in YYK1 by the
inversion on the exogenous chr3. LTF was reported to inhibit the
growth of methylcholantrene-induced mouse fibrosarcoma cells
and v-ras-transformed NIH 3T3 cells in vitro. It has also reduced the
Table 1. Tumorigenicity of KH39 and its chr3 MCHs YYK1-4 in










KH39 25y29 86 1 100
YYK1 26y84 31 5 35
YYK2 15y34 44 5 33
YYK3 16y22 73 3 19
YYK4 4y15 27 4 75
Fig. 4. (a) Microsatellite marker analysis with CER1 (3p21.3) marker D3S2354
and 3p25 marker D3S1277. A, A9Hytk3; K, KH39. (b) Average band density
ratios for four microsatellite markers. K, KH39 allele; A, A9HytK allele.























frequency of experimental metastases of melanoma cells in mice
(19). An alternatively spliced form, delta lactoferrin (DLF), is
transcribed in a variety of normal adult and fetal human tissues, but
not in 14 tumor-derived cell lines (20). Marker D3S32, located on
the same PAC RP6–19p19 as LTF, showed loss of heterozygosity
in 9y14 and 17y21 analyzed nonpapillary RCCs (21, 22), and in
several other solid tumors (5).
The telomeric border of the '15 centimorgan (cM) ER2 in the
humanyhuman MCHs (hhER2) is more proximal, because its
border marker, D3S1573, is deleted in YYK1. The centromeric
border is close to, but excludes FHIT (fragile histine triade gene)
at 3p14.2. LOH was found in ER2 in RCCs (21, 23, 24), NSCLCs
(25), and cervical carcinomas (26).
Several other regions (marked 1–4 in Fig. 3) are known to be
involved in segmental 3p losses (27): (i) 3p26-p25, which contains
the tumor suppressor gene VHL1, Von Hippel-Lindau gene (28);
(ii) 3p24-p22, which contains the mismatch repair gene MLH1,
and includes a 3p22 region involved in homozygous deletions in
NSCLC (29); (iii) 3p21.1, a second region with multiple ho-
mozygous deletions detected in SCLC and breast carcinoma
located between CER1 and ER2 immediately centromeric to the
3PK, MAP kinase-activated protein kinase (30); and (iv) at
3p14.2, putative tumor suppressor gene FHIT is known to be
inactivated in many human tumors and to be impaired in 34y34
SCID-passaged humanymouse MCHs in our system (31). None
of these regions were deleted in YYK1-derived tumors.
Four SCID passages of human chr3ymurine MCHs also
identified a CRR at 3q26-qter, spanning over 43 cM between
D3S1282 and D3S1265 (7). In the hhCRR (3q26–q27),
D3S1763, D3S3053, and D3S1262 retained heterozygosity in
16y20 YYK-derived tumors. The four exceptions have either lost
the whole exogenous chr3 or most of it. At the single cell level,
FISH has shown that 70% of the cells that have lost 3p in tumors
have retained 3q. In human tumors such as SCLC, cervical,
ovarian, bladder, kidney, and breast carcinomas, 3q isochromo-
somes, duplications, and CGH-detected gains over 3q are fre-
quently found (32, 33). Seven of nine RCC cell lines showed
CGH gains over 3q26-q27 in our experience (ref. 13 and
Kost-Alimova, unpublished observations). These findings sug-
gest that genes located in 3q26-q27 can provide tumor cells with
a selective growth advantage.
In conclusion, hhCER1 and hhER2 have been eliminated
from all 20 tumors examined in this study. The transferred
exogenous chr3 was lost in 16 tumors. In the remaining four
tumors, the situation was more complex. The exogenous 3p was
eliminated from a subpopulation of cells, whereas one of the two
endogenous 3p was lost in the rest. In all, YYK2, -3, and
-4-derived tumors, the ratio of exo- to endogenous 3p losses was
'80% to '20%. If the losses occurred randomly, this ratio
would be 1:2, because YYKs contain one exogenous and two
endogenous copies of chr3. Loss of the exogenous 3p is thus
clearly preferred, but gene dosage effects, perhaps in combina-
tion with epigenetic inactivation, may also modulate the loss of
the tumor antagonizing function attributed to 3p. This is con-
sistent with the fact that human solid tumors frequently show 3p
losses, but rarely gains, as judged by CGH (33).
Our results on the human chr3ymouse tumor and the human
chr3yhuman tumor cell MCHs converge, indicating that the elim-
ination of hhCER1 and hhER2 is regularly associated with tumor
growth. It is noteworthy, however, that YYK1 has lost these regions
already in vitro and showed a reduced take incidence and prolonged
latency period in vivo. This suggests that 3p genes outside our
eliminated regions may antagonize tumor growth as well.
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